Fig. 2

Drugs used in endocrine treatment of breast cancer. Schematic diagram of current and novel drugs currently in clinical trial with their target signalling molecules. CDK cyclin-dependent kinase, E2 oestradiol-17 beta, EGFR epidermal growth factor receptor, ER oestrogen receptor, HDAC histone deacetylase, HER2 human epidermal growth factor receptor, IGF-1R insulin-like growth factor-1 receptor, MAPK mitogen-activated protein kinase, mTOR mammalian target of rapamycin, PI3K phosphoinositide-3-kinase, SERD selective oestrogen receptor degrader, SERM selective oestrogen receptor modulator, T testosterone, VEGF vascular endothelial growth factor, VEGFR VEGF receptor